10
Weng TC, et al. J Clin Pharm Ther 2010;35:139- 51

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Embed Size (px)

Citation preview

Page 1: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 2: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Baseline characteristics of statin studies with paired-comparisons

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 3: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Comparisons of the lipid lowering effect of different statins: LDL

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 4: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Comparisons of the lipid lowering effect of different statins: HDL

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 5: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Comparisons of the lipid lowering effect of different statins: TG

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 6: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Low density lipoprotein (LDL) reduction (%) of different statins in different doses

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 7: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Weighted mean difference (WMD) with 95% confidence interval (CI) of different statins at equivalent dose

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 8: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Effects on cardiovascular events

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 9: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Incidence of specific adverse effects (%)

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Page 10: Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Flow chart of the article selection

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51